Pentosidine in chronic hemodialysis patients: relation with arteriovenous fistula morphology and function

Ticala, Maria; Tirinescu, Dacian; Rusu, Crina; Moldovan, Diana; Potra, Alina; Coman, Andreea Codruta; Bondor, Cosmina Ioana; Budişan, Liviuţa; Kacsó, Ina Maria

doi:10.1007/s11255-019-02151-z

Cited by 3 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taking this into account, as well as the strong correlation of sRAGE to VCAM-1 there is probably no significant added value in determining multiple biomarkers as predictors of AVF function. Similar to the above-mentioned studies, 10,12 we evaluated serum levels of these molecules, inferring a link between local expression at the vascular access site and systemic increase. However, this remains to be proven, as the few studies that evaluated expression in AVF tissue did not study serum levels of the same.…”

Section: Discussionmentioning

confidence: 92%

“…11 In a previous study, we showed that a higher level of pentosidine, other AGEs, was related to the development of AVF stenosis in hemodialysis patients. 12 AGEs interact with their multi ligand-receptor named receptor for advanced glycation end products (RAGE). RAGE can be identified in serum as a soluble receptor for advanced glycation end products (sRAGE).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Relationship between vascular cell adhesion molecule-1 (VCAM-1), soluble receptor for advanced glycation end products (sRAGE) and functional hemodynamic parameters of arteriovenous fistula

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: The preferred vascular access for hemodialysis is represented by arteriovenous fistula (AVF) due to fewer complications and more prolonged survival. Considerable efforts have been made to identify biomarkers associated with AVF dysfunction, but results are conflicting. Vascular cell adhesion molecule (VCAM-1) and advanced glycation end products are involved in atherogenesis, vascular calcification, peripheral artery disease, and neointimal hyperplasia in renal and non-renal patients. The objective of this study was to evaluate whether there is an association between VCAM-1, soluble receptor for advanced glycation end products (sRAGE), NcarboxymethylLysine (CML), and arteriovenous fistula dysfunction (AVF). Methods: VCAM-1, sRAGE, and CML were performed using the ELISA technique in 88 HD patients. Ultrasound assessment of AVF reports brachial artery blood flow (Qa), brachial resistivity index (RI), presence of calcification, and the diameter. AVF dysfunction was defined as a brachial artery Qa ⩽ 500 ml/min or RI ⩾ 0.5. Results: The median level of VCAM-1 [2676.5(2206.8–4203.9) versus 2613.2(1885.7–3161.8), p 0.026] was significantly higher in patients with AVF dysfunction compared to the rest of the patients. sRAGE and CML were higher in this group but without statistical significance. In patients with AVF dysfunction, significant positive correlations were found between VCAM-1and sRAGE ( r = 0.417, p = 0.001), RI ( r = 0.313, p = 0.046), dialysis vintage ( r = 0.540, p < 0.001), AVF vintage ( r = 0.336, p = 0.032), intima-media thickness ( r = 0.423, p = 0.006) and C-reactive protein ( r = 0.315, p = 0.045). VCAM-1 correlated inversely with cholesterol ( r = −0.312, p = 0.047), triglycerides ( r = −0.358, p = 0.021), body mass index ( r = −0.388, p = 0.012). In multivariate regression analysis, VCAM-1 ( p = 0.013) and sRAGE ( p = 0.01) remained significant predictors of RI and Qa. Logistic regression disclosed calcification, VCAM-1, as risks factors for AVF dysfunction. Conclusion: The results we obtained showed that patients with AVF dysfunction had a significantly higher level of VCAM-l. A positive correlation between VCAM-1 and sRAGE was identified in this group.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Relationship between vascular cell adhesion molecule-1 (VCAM-1), soluble receptor for advanced glycation end products (sRAGE) and functional hemodynamic parameters of arteriovenous fistula

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…In fact, a cross‐sectional observational study of patients with type 1 diabetes showed that the group with a high concentration of both types of AGEs, namely Nε‐carboxyethyllysine and pentosidine, showed many diabetic complications, including nephropathy, neuropathy and cardiovascular disease 5,6,19 . Furthermore, the group with a high level of serum pentosidine among patients undergoing dialysis showed a significantly higher frequency of novel vascular events 20 …”

Section: Discussionmentioning

confidence: 99%

Association of advanced glycation end‐products levels with vascular events in postmenopausal women

Urano

Shiraki²,

Imai

et al. 2021

Geriatrics Gerontology Int

View full text Add to dashboard Cite

Aim Advanced glycation end‐products (AGEs) are a known factor that accelerates vascular complications. AGEs (e.g. pentosidine or N‐ε‐carboxy‐methyl‐lysine [CML]) have been particularly investigated in patients with diabetes or chronic kidney disease and have been associated not only with arteriosclerosis, but also with novel vascular events. On the contrary, the correlation of vascular events with AGEs has not been sufficiently investigated in groups excluding those with diabetes or chronic kidney disease. The present study aimed to evaluate the impact of AGEs on the history of vascular events in postmenopausal women excluding those with diabetes or renal insufficiency. Methods Japanese postmenopausal women were registered to the study after obtaining informed consent. Patients with critical illness, including diabetes mellitus and renal insufficiency, were excluded from the study. Participants were asked about their medical histories during the registration for the Nagano Cohort Study. Non‐fasting serum and urine samples were collected to measure biochemical markers, including urinary pentosidine and serum CML levels. Results Among 357 postmenopausal women, 32 had a history of vascular events. After adjusting age and other variables known to be associated with the presence of vascular event history, positive correlations between AGEs and vascular event history were observed (standardized odds ratio of log[pentosidine] 1.38, 95% CI 0.96–2.00, P = 0.086; standardized odds ratio of log[CML] 1.73, 95% CI 1.10–2.74, P = 0.019). Discussion The present results showed a significant association between serum CML and the presence of vascular event history, suggesting that serum CML might play a role in vascular events. Geriatr Gerontol Int 2021; 21: 651–656.

show abstract

“…The median baseline value for sRAGE was 14.43 (range 11.90–17.60). More about the baseline characteristics are depicted in our previous cross-sectional study [12].…”

Section: Methodsmentioning

confidence: 99%

Hemodialysis Patients with Higher Serum Levels of Soluble Receptor for Advanced Glycation End Products Have an Increased Risk for Arteriovenous Fistula Failure

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Arteriovenous fistula (AVF) failure due to thrombosis is a major cause of morbidity in patients undergoing regular hemodialysis (HD). Advanced glycation end products (AGEs) and their receptor (RAGE) might contribute to inflammation, neointimal hyperplasia, and thrombosis. RAGE has a C-truncated secretory receptor form, called soluble RAGE (sRAGE). In this study, we aimed to evaluate the association of serum sRAGE with AVF failure due to thrombosis in HD patients. Methods: Eighty-eight prevalent HD patients with functional AVF were included in the study. The presence of stenosis, clinical and laboratory data, and serum sRAGE was evaluated at inclusion. sRAGE concentration was measured by a competitive enzyme-linked immunosorbent assay, and stenosis was detected by ultrasound. Patients were prospectively followed up for 36 months. During this period, AVF failure (defined as the absence of blast or palpable thrill and impossible cannulation with 2 needles because of complete thrombosis) was noted and thrombosis was certified by ultrasound examination. Results: During follow-up, 16 (18.18%) patients lost their vascular access due to thrombosis. In multivariate Cox regression analysis, sRAGE was a significant predictor of vascular access thrombosis (hazard ratio = 1.15, 95% confidence interval: 1.03–1.25, p = 0.012). Kaplan-Meier analysis showed a significantly lower AVF patency time in patients with sRAGE >16.78 ng/mL than those with sRAGE <16.78 ng/mL (p = 0.02). In the subgroup of patients with stenosis at baseline, sRAGE, serum albumin, obesity, and ischemic heart disease were associated with thrombosis. Conclusion: In our study, baseline, systemic sRAGE is associated with the occurrence of thrombosis of AVF, and this marker has a significant impact on AVF survival.

show abstract

Pentosidine in chronic hemodialysis patients: relation with arteriovenous fistula morphology and function

Cited by 3 publications

References 41 publications

Relationship between vascular cell adhesion molecule-1 (VCAM-1), soluble receptor for advanced glycation end products (sRAGE) and functional hemodynamic parameters of arteriovenous fistula

Relationship between vascular cell adhesion molecule-1 (VCAM-1), soluble receptor for advanced glycation end products (sRAGE) and functional hemodynamic parameters of arteriovenous fistula

Association of advanced glycation end‐products levels with vascular events in postmenopausal women

Hemodialysis Patients with Higher Serum Levels of Soluble Receptor for Advanced Glycation End Products Have an Increased Risk for Arteriovenous Fistula Failure

Contact Info

Product

Resources

About